# KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

> **NCT00646139** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma
- Lymphoproliferative Disorder
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** Src kinase inhibitor KX2-391
- **OTHER:** immunoenzyme technique
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00646139
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-08
- **Final completion:** 2009-03
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2011-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646139, "KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00646139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*